---
title: 'Real-World Characteristics of Patients with Severe Asthma prior to Starting
  Dupilumab: The ProVENT Study'
date: '2023-12-12'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38086344/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231213170709&v=2.18.0
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: This analysis suggests that patients eligible for dupilumab
  treatment display various clinical and biochemical characteristics rather than one
  clear-cut ...'
disable_comments: true
---
CONCLUSIONS: This analysis suggests that patients eligible for dupilumab treatment display various clinical and biochemical characteristics rather than one clear-cut ...